The laboratory uses the nematode Caenorhabditis elegans as an experimental model for the study of the molecular mechanisms underlying the aggregation of amyloidogenic proteins, involved in central and systemic amyloidosis. The final goal is to identify new molecular targets and develop new therapeutic approaches. We strictly collaborate with other translational researchers and clinicians so that the results of our research can be translated into clinical practice.
Development of new animal models for the study of central and systemic amyloidosis
The worm Caenorhabditis elegans, about 1 mm in length, share with humans some cellular and molecular mechanisms. About 60% of the genes involved in human diseases are present also in C. elegans. It can be easily genetically engineered, allowing the generation of new models for the study of human diseases. Since it is a simple, invertebrate animal, the studies using C. elegans are not restrained by the ethical issues pertaining to animal experimentation.
Study of diffusion of amyloidogenic proteins and their toxicity
We study the processes through which amyloidogenic protein clusters migrate from one cell to another, transferring their toxic potential and accumulating in tissues. These pathogenetic mechanisms are crucial for numerous amyloidoses, such as Alzheimer's disease, tauopathies and dementia, in particular in relation to the occurrence of a cranial injury.
New therapeutic strategies for immunoglobulin light chain amyloidosis
Caenorhabditis elegans is a basic model for the study of immunoglobulin light chain amyloidosis. We investigate the relation between the degenerative process associated with the proteotoxicity of immunoglobulin light chains in the different phases of the disease. Thus, we aim to develop new efficient pharmacological approaches and translate them to the clinic.
International Consensus on Cardiopulmonary Resuscitation.